Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of XL647 in Subjects With Non-Small-Cell Lung Cancer.

Trial Profile

A Phase 2 Study of XL647 in Subjects With Non-Small-Cell Lung Cancer.

Phase of Trial: Phase II

Latest Information Update: 07 Dec 2011

At a glance

  • Drugs Tesevatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Sep 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
    • 23 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Jan 2010 Preliminary data from this phase 2 study were presented at AACR-IASLC Conference on the Molecular Origins of Lung Cancer, according to a Symphony Evolution Inc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top